Drug Combo May Boost Melanoma Survival, Lessen Side Effects
This article is for subscribers only.
Adding a white-blood cell boosting treatment from Sanofi to Bristol-Myers Squibb Co.’s melanoma drug Yervoy helped patients with advanced skin cancer live longer and lessened side effects, a study found.
In the trial of 245 patients led by researchers at the Dana-Farber Cancer Institute in Boston, 68.9 percent of patients who got Yervoy, designed to spur the immune system to attack cancer cells, and the Sanofi drug, GM-CSF, were alive one year later, compared to 52.9 percent of those who got Yervoy alone.